bpc 157 for als BPC-157 — Evolved Science BPC-157 – Research Peptide |

DSIP was tested at final peptide concentrations of 10, 10, 10, and 10 M

Pregnant or breastfeeding individuals No safety data exists for cagrilintide use during pregnancy or breastfeeding

What to track at each dose tier Record these metrics weekly throughout your escalation: Body weight: Same day, same time, same conditions (morning, fasted, after bathroom) Waist circumference: Most reliable non-scale metric for fat loss Appetite level: Rate 1-10 daily, average weekly Side effects: Type, severity, duration, timing relative to injection Energy level: Rate 1-10 daily, average weekly Injection volume and site: Document every injection for reference This data becomes invaluable at decision points

The optimal dose is the lowest dose that produces the desired clinical effect with acceptable tolerability